Nasus Pharma Ltd. (NSRX)

NYSEAMERICAN: NSRX · Real-Time Price · USD
8.05
-0.01 (-0.12%)
At close: Aug 28, 2025, 4:00 PM
8.05
0.00 (0.00%)
After-hours: Aug 28, 2025, 4:10 PM EDT
-0.12%
Market Cap72.57M
Revenue (ttm)n/a
Net Income (ttm)-1.53M
Shares Out 9.06M
EPS (ttm)-0.22
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume22,864
Open8.09
Previous Close8.06
Day's Range7.97 - 8.20
52-Week Range7.23 - 9.99
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About NSRX

Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company’s products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and i... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 14, 2025
Employees 2
Stock Exchange NYSEAMERICAN
Ticker Symbol NSRX
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony

TEL AVIV, Israel, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative i...

2 days ago - GlobeNewsWire

U.S. IPO Weekly Recap: Bullish And Miami International Complete The Last Major IPOs Of The Summer

Eight issuers listed in the US this past week, six of which were eligible for inclusion in our IPO stats, joined by two SPACs. There are no IPOs currently scheduled for the week ahead, though some sma...

12 days ago - Seeking Alpha

Nasus Pharma Announces Closing of Initial Public Offering

TEL AVIV, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative i...

14 days ago - GlobeNewsWire

Nasus Pharma Announces Pricing of $10 Million Initial Public Offering

TEL AVIV, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative i...

15 days ago - GlobeNewsWire

Nasus Pharma IPO Shows Promise But Risks Remain

Nasus Pharma is developing a needle-free intranasal epinephrine spray for severe allergies, showing promising but early trial results in a small population. The company is thinly capitalized, faces a ...

6 weeks ago - Seeking Alpha

Israeli severe allergy biotech Nasus Pharma files and sets terms for an $11 million US IPO

Nasus Pharma, a Phase 2 biotech developing an intranasal powder for severe allergies and anaphylaxis, filed on Wednesday with the SEC to raise up to $11 million in an initial public offering.

7 weeks ago - Renaissance Capital

Nasus Pharma IPO Registration Document (F-1)

Nasus Pharma has filed to go public with an IPO on the NYSE American.

7 weeks ago - SEC